Shanghai, China - February 9, 2026 - MicroPort CardioFlow Medtech Corporation (02160.HK, “MicroPort CardioFlow”) announced today the commercial launch of the FLEXIGO™ 3D delivery system designed to support Left Bundle Branch Area Pacing (LBBAP) procedures, in Europe and Australia.
LBBAP which leverages the heart’s natural conduction system, is increasingly recognized as the preferred approach to physiological pacing¹. The FLEXIGO™ 3D system is designed to support physicians in performing these procedures with controlled2,3,4 navigation and targeted LBBAP lead positioning5, facilitating consistent access to the desired anatomical region.
Building on clinical validation and subsequent regulatory clearances, FLEXIGO™ 3D is now available for commercial use in Europe and Australia markets. The FLEXIGO™ 3D system combines a delivery catheter portfolio with eight available models and dedicated slitters, forming one cohesive solution designed to support precise LBBAP lead placement. The system is engineered to provide confidence and handling control2 throughout lead delivery, supporting physiological pacing across a variety of patient anatomies and lead profiles.
The FLEXIGO™ 3D system was developed under the Legacy Cardiac Rhythm Management (CRM) division of MicroPort and builds upon the company’s established leadership in physiological pacing solutions. In 2024, MicroPort CRM received expanded labeling for its ALIZEA™, BOREA™, and CELEA™ pacemaker families for Left Bundle Branch Area Pacing, reinforcing its commitment to advancing conduction system pacing technologies.
MicroPort CardioFlow will continue to advance its globalization strategy, further supported by its recently announced strategic merger with MicroPort CRM. The combined capabilities of both companies aim to establish a comprehensive platform in structural heart, cardiac rhythm management (CRM), and heart failure, accelerating access to life-changing technologies worldwide.
MicroPort CRM is now in the family of MicroPort CardioFlow.
About MicroPort CardioFlow:
MicroPort CardioFlow is a global leader in innovation within the field of structural heart intervention and cardiac rhythm management. While continuously solidifying its absolute leading position in China's TAVI market and its innovative pipeline advantage across all valvular disease treatments, the company is deeply integrating MicroPort CRM's over 60 years of professional expertise, its 12 core product pipelines, and its global portfolio of more than 40 marketed products covering pacemakers, ICDs, and other areas. It is fully committed to building a world-leading integrated platform spanning “structural heart intervention, rhythm management, and heart failure care," thereby constructing a comprehensive device-based management solution for heart failure that covers all etiologies, all stages, and the entire care cycle. By providing physicians and patients with innovative, full-cycle heart failure health management services, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.
More information is available at: https://en.cardioflowmedtech.com/
About MicroPort CRM:
MicroPort CRM is a global leader in the field of cardiac rhythm management, headquartered in Clamart, near Paris, France. With more than 60 years of expertise and continuous innovation, MicroPort CRM currently boasts 12 pipelines and over 40 marketed products across core cardiac rhythm management segments, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and Holter ECG diagnostic solutions.
More information is available at: https://en.cardioflowmedtech.com/about/zigongsijianjie
References:
*POLARIS study (EU Identification Number: CIV-FR-25-01-050957): The usability of the FLEXIGO™ delivery catheter and the FLEXIGO™ slitter during the pacing lead implantation was documented through a questionnaire that each investigator (n=12) had to fill-in after each implantation. 75 questionnaires were analyzed, corresponding to the 75 patients enrolled in the study. The investigators had to rank product usability with ‘Very good / Good / Acceptable / Poor / Very poor / Not Applicable’. The satisfaction rate is expressed by the percentage of ‘Very good+good+Acceptable’ (CLINICAL INVESTIGATION REPORT PRIMARY ENDPOINT RESULTS PHASE I – internal file)